Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06089395
Other study ID # JJGS on POR
Secondary ID
Status Not yet recruiting
Phase Early Phase 1
First received
Last updated
Start date June 1, 2024
Est. completion date August 31, 2025

Study information

Verified date April 2024
Source Dongzhimen Hospital, Beijing
Contact Shi Y Shi Yun, phD
Phone 13717926522
Email zhyshiyun@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Relying on the Department of Gynecology of Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine and chaoyang hospital of Capital medical university, this randomized controlled clinical study was carried out to investigate the application of kidney tonifying herbs to patients with poor ovarian response(POR). A total of 76 patients with POR were collected and stratified district groups were randomly divided into a test group and a control group, with 38 patients included in each group. The experimental group was intervented with JJGS granules + coenzyme Q10 simulant, and the control group was intervened with coenzyme Q10 + JJGS granules simulant. AMH, serum basal sex hormone, AFC, TCM syndrome score, modified Kupperman scale and pregnancy status were observed before and after treatment to investigate the effects of Jiajian Guishen granules on the ovarian function of POR patients.


Description:

This study was a multicenter, stratified block randomized, double-blind, double simulation, positive controlled clinical trial.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 76
Est. completion date August 31, 2025
Est. primary completion date August 31, 2025
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 45 Years
Eligibility Inclusion Criteria: 1. Woman who meet the diagnostic criteria for poor ovarian response; 2. Woman who meet the TCM diagnostic criteria for kidney deficiency; 3. Woman whose serum basal FSH(two consecutive menstrual cycles)between 10-25mIU/mL 4. Woman whose AMH <1.1ng/ml; 5. Woman aged ranged from 20-45 years old 6. Woman whose body mass index (BMI)<35 kg/m2 7. Womanwho voluntarily signed the informed consent form. Exclusion Criteria: 1. Woman who have combination of serious diseases such as cardiovascular, cerebrovascular, hepatic, renal and hematopoietic systems, and malignant tumors; 2. Woman who have other endocrine diseases, such as polycystic ovary syndrome and hyperprolactinemia; 3. Woman who are unable to cooperate with the treatment and follow-up, such as combined neurological and psychiatric disorders, or those who are unwilling to cooperate. 4. Woman who have used the same efficacy of herbs or other therapies in the last 1 month; 5. Woman who are allergic to the drugs used in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Jiajian Guishen granules
This study was a stratified district group randomized, double-blind, double simulation, positive control clinical trial with JJGS granules + coenzyme Q10 simulant in the test group and JJGS granules simulant + coenzyme Q10 in the control group
coenzyme Q10
This study was a stratified district group randomized, double-blind, double simulation, positive control clinical trial with JJGS granules + coenzyme Q10 simulant in the test group and JJGS granules simulant + coenzyme Q10 in the control group

Locations

Country Name City State
China Chaoyang Hospital Affiliated to Capital Medical University Beijing
China Dongzhimen Hospital of Beijing University of Chinese Medicine Beijing Beijing

Sponsors (2)

Lead Sponsor Collaborator
Shi Yun Capital Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Anti-Miller's Tube Hormone(AMH) The unit is ng/mL.Elbow vein blood was collected on an empty stomach, and after separating the serum, anti-mullerian hormone (AMH) was measured by radioimmunoassay before treatment and the first menstrual period 2-4 days after treatment
Secondary Follicle-stimulating hormone(FSH) The unit is mIU/mL.Elbow vein blood was collected on an empty stomach, and after separating the serum, FSH were measured by radioimmunoassay. before treatment and the first menstrual period 2-4 days after treatment
Secondary Luteinizing hormone(LH) The unit is mIU/mL.Elbow vein blood was collected on an empty stomach, and after separating the serum, LH were measured by radioimmunoassay. before treatment and the first menstrual period 2-4 days after treatment
Secondary Estrogen (E2) The unit is pg/mL.Elbow vein blood was collected on an empty stomach, and after separating the serum, E2 were measured by radioimmunoassay. before treatment and the first menstrual period 2-4 days after treatment
Secondary Progesterone (P) The unit is ng/mL.Elbow vein blood was collected on an empty stomach, and after separating the serum, P were measured by radioimmunoassay. before treatment and the first menstrual period 2-4 days after treatment
Secondary Testosterone(T) The unit is ng/mL.Elbow vein blood was collected on an empty stomach, and after separating the serum, T were measured by radioimmunoassay. before treatment and the first menstrual period 2-4 days after treatment
Secondary antral follicle count(AFC) Color Doppler ultrasound was performed in the early follicular phase in the usual way to observe the number of follicles in the underlying sinuses. before treatment and early follicular phase in the first post-treatment menstrual cycle day 1
Secondary Traditional Chinese Medicine Score The main symptoms include menstrual cycle, menstrual flow reduction. Scoring criteria: ? normal menstrual cycle 0 points, 1-2 weeks ahead or behind the wrong 4 points, 2-3 weeks 8 points, more than 3 weeks 12 points; ? menstrual flow than the previous menstrual flow no change 0 points, menstrual flow reduction = ? 4 points, ? < menstrual flow reduction = ½ 8 points, menstrual flow reduction > ½ 12 points. Secondary symptoms included lumbar and knee pain, dizziness and tinnitus, loss of libido, increased urination, hot flashes and night sweats, and lower back and lower limb pain. According to the degree of aggravation of symptoms, the total score was assigned as 0,2,4,8. The sum of the scores of the main symptoms and secondary symptoms, the higher the score, the more serious the TCM symptoms. baseline and immediately after treatment
Secondary Modified Kupperman rating scale Referring to the domestic modified Kupperman Symptom Scoring Criteria in Chinese Obstetrics and Gynecology, edited by Cao Zeyi, to observe and rate perimenopausal symptoms before and after treatment and to quantify the degree of decline in ovarian function.Entries include hot flashes and sweating, sensory abnormalities, insomnia, anxiety and depression, dizziness, fatigue, muscle and joint pain, headache, palpitations, ankylosis of the skin, sexual discomfort, and urinary irritation, with different coefficients for each entry, and according to the aggravating degree of the symptom, they are divided into 0, 1, 2, and 3 points, and the coefficients corresponding to the scoring of the degree of each item are multiplied by a fixed score of the symptom to add up to the total score, and the higher the total score suggests that the symptoms of the perimenopausal period are more serious. baseline and immediately after treatment
Secondary Clinical pregnancy rate Defined as the number of women with identified clinical pregnancies divided by the number of patients randomized to a specific group. Clinical pregnancy is confirmed when 1 or more ges-tational sacs are detected on transvaginal ultrasound assessment. up to 6 months
Secondary Early miscarriage rate Defined as the per-centage of participants with loss of a diagnosed clinical pregnancy before 12 weeks gestation to the total patients randomized up to 6 months
See also
  Status Clinical Trial Phase
Completed NCT03433768 - Androgen Receptor mRNA Expression is Positively Associated With Live Birth in Women Undergoing IVF Independently of the Type of Ovarian Response N/A
Recruiting NCT05601193 - Ovarian PRP Injection in Women With POR N/A
Suspended NCT03021915 - Single Center, Prospective Controlled Pilot Study of the OvaPrime Procedure N/A
Completed NCT04013984 - Acupuncture for Treatment of Patients With Poor Ovarian Response N/A
Completed NCT03447184 - Long-term Endogenous Androgen Priming in Bologna Criteria Poor Responder Patients - A Pilot Study
Completed NCT01816321 - Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders Trial Phase 3
Recruiting NCT04310293 - Novel Therapy for Poor Responders Management N/A
Completed NCT05703308 - Menstrual Blood Stem Cells in Poor Ovarian Responders Phase 3
Terminated NCT00878124 - How Dose Coenzyme Q10 Supplementation During Infertility Treatment Effects Pregnancy Outcome N/A
Completed NCT01732068 - Treatment of Poor Ovarian Responders With Corifollitropin Alfa Followed by hpHMG in a Short GnRH Agonist Protocol Phase 2
Completed NCT01732094 - Corifollitropin Alfa Followed by hpHMG in a Long GnRH Agonist Protocol for the Treatment of Poor Ovarian Responders Phase 2
Recruiting NCT04717752 - A Randomized Controlled Study of Different Trigger Modes of Antagonist Regimen in Patients With Low Ovarian Reserve N/A
Recruiting NCT04024722 - Improving in Vitro Fertilization in Women With Poor Ovarian Response N/A
Completed NCT03994614 - the Effect of Transcutaneous Electrical Acupoint Stimulation on the Quality of Oocyte on Poor Ovarian Response(POR) N/A
Recruiting NCT03830697 - A Trial Study on Acupuncture Treatment of Poor Ovarian Response N/A
Recruiting NCT02801591 - Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ET N/A
Recruiting NCT04273256 - Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT02993588 - Impact of Melatonin on IVF/ICSI Outcomes in Prospective Poor Responders Phase 2/Phase 3
Terminated NCT02418572 - Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial Phase 3